Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Shares Down 4.9% – Time to Sell?

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) was down 4.9% during mid-day trading on Tuesday . The company traded as low as $5.03 and last traded at $5.03. Approximately 573,880 shares changed hands during trading, a decline of 33% from the average daily volume of 858,881 shares. The stock had previously closed at $5.29.

Analyst Ratings Changes

Several research firms have recently commented on SENS. Stifel Nicolaus decreased their target price on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Weiss Ratings cut shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Finally, HC Wainwright cut their price target on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Senseonics Holdings, Inc. Common Stock Price Performance

The company has a market cap of $210.25 million, a price-to-earnings ratio of -2.52 and a beta of 0.99. The stock has a fifty day simple moving average of $6.12. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.51.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06). The company had revenue of $11.71 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 213.87% and a negative return on equity of 129.97%. On average, sell-side analysts expect that Senseonics Holdings, Inc. Common Stock will post -2.38 EPS for the current fiscal year.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In other news, Director Douglas A. Roeder bought 22,686 shares of the stock in a transaction dated Tuesday, May 12th. The stock was bought at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the acquisition, the director directly owned 144,635 shares in the company, valued at approximately $804,170.60. This trade represents a 18.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. Cetera Investment Advisers bought a new stake in Senseonics Holdings, Inc. Common Stock in the 1st quarter worth about $85,000. Captrust Financial Advisors purchased a new stake in Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at about $77,000. Hudson Bay Capital Management LP bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $85,000. GSK plc bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. Finally, Ausdal Financial Partners Inc. boosted its stake in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after buying an additional 35,000 shares during the last quarter. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.